Dynamics of SARS-CoV-2 Immunoglobulin G Antibody Among Hospitalized Patients and Healthcare Workers During the Delta Wave in Bangladesh
Cureus,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 13, 2025
Language: Английский
Compartmentalised mucosal and blood immunity to SARS-CoV-2 associated with high seroprevalence before Delta wave in Africa
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 14, 2024
Abstract
Background
The
reported
number
of
SARS-CoV-2
cases
and
deaths
are
lower
in
Africa
compared
to
many
high-income
countries.
However,
African
cohorts,
detailed
characterisation
mucosal
T
cell
immunity
limited.
We
assessed
SARS-CoV-2-specific
immune
landscape
Gambia
pre-Delta
variant
July
2021.
Methods
A
cross-sectional
assessment
349
unvaccinated
individuals
from
52
Gambian
households
was
performed
between
March
-
June
spike
(S)
nucleocapsid
(N)
specific
binding
antibodies
were
measured
by
ELISA,
variant-specific
serum
neutralizing-antibodies
(NAb)
viral
pseudotype
assays
nasal
fluid
IgA
mesoscale
discovery
assay.
T-cell
responses
evaluated
using
ELISpot
Results
show
that
adjusted
seroprevalence
anti-Spike
56.7%
(95%
confidence
interval
(CI)
49.0–64.0),
which
children
<
5
years
(26.2%,
13.9–43.8)
5–17
(46.4%,
36.2–56.7)
adults
18–49
(78.4%,
68.8–85.8).
In
spike-seropositive
individuals,
NAb
titres
highest
Alpha
(median
IC50
110),
with
27%
showing
pre-existing
Delta
>
1:50.
Whilst
significantly
higher
34%
spike-seronegative
showed
reactivity
one
or
more
antigen
pools.
Strong
correlations
within
T-cell,
IgA,
observed.
Conclusion
High
The-Gambia
induced
blood
immunity,
reducing
Omicron
impact.
Children
relatively
protected
infection.
seronegative
may
indicate
either
pre-pandemic
cross-reactivity
a
dominated
response
infection
absent
poor
humoral
responses.
Language: Английский
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.
iScience,
Journal Year:
2024,
Volume and Issue:
27(9), P. 110728 - 110728
Published: Aug. 14, 2024
CombiVacS
study
has
demonstrated
a
strong
immune
response
of
the
heterologous
ChAdOx1-S/BNT162b2
vaccine
combination.
The
primary
outcomes
were
to
assess
humoral
against
SARS-CoV-2,
28
days
after
third
dose
mRNA
vaccine,
in
subjects
that
received
previous
prime-boost
scheme
with
ChAdOx1-S/BNT162b2.
Secondary
extended
3
and
6
months.
mRNA-1273
naive
participants
previously
vaccinated
regimen
reached
higher
neutralizing
antibodies
titers
variants
concern
Delta
BA.1
lineage
Omicron
compared
those
receiving
BNT162b2
at
day
28.
These
differences
between
arms
observed
ancestral
variant
G614
90.
Suboptimal
was
BQ.1.1,
XBB.1.5/XBB.1.9,
JN.1
relevant
proportion
individuals
180
dose,
even
asymptomatic
breakthrough
infections.
EudraCT
(2021-001978-37);
ClinicalTrials.gov
(NCT04860739).
Language: Английский